ARCTIC BIOSCIENCE |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.5 NOK | 0.00% |
|
+6.60% | 0.00% |
| Mar. 01 | Arctic Bioscience AS Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Mar. 01 | Transcript : Arctic Bioscience AS, Q4 2023 Earnings Call, Mar 01, 2024 |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Capitalization 1 | 432.5 | 287.6 | 266.4 | 266.4 | - |
| Enterprise Value (EV) 1 | 205.2 | 143.5 | 186.8 | 109.4 | 160.4 |
| P/E ratio | -10.2 x | -8.49 x | -5.87 x | -8.73 x | -5.27 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | 19.7 x | 8.39 x | 7.89 x | 4.67 x | 3.37 x |
| EV / Revenue | 9.33 x | 4.19 x | 5.53 x | 1.92 x | 2.03 x |
| EV / EBITDA | -7 x | -4.63 x | -4.84 x | -5.96 x | -4.18 x |
| EV / FCF | -2.7 x | - | -2.18 x | -3.53 x | -3.21 x |
| FCF Yield | -37% | - | -45.8% | -28.3% | -31.2% |
| Price to Book | - | - | - | - | - |
| Nbr of stocks (in thousands) | 24,300 | 24,376 | 25,370 | 25,370 | - |
| Reference price 2 | 17.80 | 11.80 | 10.50 | 10.50 | 10.50 |
| Announcement Date | 2/18/22 | 3/29/23 | 3/1/24 | - | - |
1NOK in Million2NOK
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net sales 1 | 20.59 | 22 | 34.27 | 33.75 | 57 | 79 |
| EBITDA 1 | - | -29.29 | -31 | -38.6 | -18.35 | -38.41 |
| EBIT 1 | - | -31.81 | -34.73 | -43.98 | -25.28 | -45.34 |
| Operating Margin | - | -144.59% | -101.33% | -130.31% | -44.34% | -57.39% |
| Earnings before Tax (EBT) 1 | - | -42.58 | -34.02 | -45.51 | -30.51 | -50.58 |
| Net income 1 | -22.59 | -42.58 | -34.02 | -45.51 | -30.51 | -50.58 |
| Net margin | -109.7% | -193.54% | -99.28% | -134.86% | -53.53% | -64.02% |
| EPS 2 | - | -1.750 | -1.390 | -1.790 | -1.203 | -1.994 |
| Free Cash Flow 1 | - | -76 | - | -85.62 | -31 | -50 |
| FCF margin | - | -345.44% | - | -253.69% | -54.39% | -63.29% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - |
| Announcement Date | 2/1/21 | 2/18/22 | 3/29/23 | 3/1/24 | - | - |
1NOK in Million2NOK
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | - | 227 | 144 | 79.6 | 157 | 106 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | - | -76 | - | -85.6 | -31 | -50 |
| ROE (net income / shareholders' equity) | - | -22.1% | -11.2% | -16.7% | -11% | -17.6% |
| ROA (Net income/ Total Assets) | - | -19.6% | -10.2% | -14.5% | -9.2% | -14.6% |
| Assets 1 | - | 217.3 | 334.6 | 314 | 331.7 | 346.4 |
| Book Value Per Share | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - |
| Capex 1 | - | 36.5 | - | 45.3 | 5 | 5 |
| Capex / Sales | - | 165.91% | - | 134.32% | 8.77% | 6.33% |
| Announcement Date | 2/1/21 | 2/18/22 | 3/29/23 | 3/1/24 | - | - |
1NOK in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
10.5
NOK
Average target price
10
NOK
Spread / Average Target
-4.76%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| 0.00% | 24.57M | |
| +26.08% | 662B | |
| +21.85% | 546B | |
| -4.77% | 359B | |
| +16.97% | 323B | |
| +5.69% | 290B | |
| +13.68% | 234B | |
| +3.65% | 198B | |
| -11.12% | 194B | |
| +8.08% | 167B |
- Stock Market
- Equities
- ABS Stock
- Financials Arctic Bioscience
